Frontlight ResearchEarly access
CompletedPhase 2
A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance (SafeDoxyPEP trial)
Key facts
- Who runs it
- Institute Of Tropical Medicine
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 78 people enrolled
- Started
- 13 Mar 2024
- Ended
- 19 Jun 2025
- Type of study
- Interventional
- Record updated
- 7 March 2024
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Able and willing to provide written informed consent
- Age 18 years old or older
- Eligible to take HIV PrEP
- Male sex at birth
Who cannot take part
- Use of any antibiotics in the previous 3 months
- Currently using or planning to use anticoagulants based on vitamin K antagonism (warfarin, acenocoumarol, fenprocoumon)
- Known contra-indications or allergy to doxycycline, gluten or lactose
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Assess if doxycycline PEP can result in reduced susceptibility to doxycycline in rectal E. coli on day 180
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance
- Record updated
- 7 March 2024